Vanguard Group Inc Cyclo Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Cyclo Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 598,694 shares of CYTH stock, worth $413,098. This represents 0.0% of its overall portfolio holdings.
Number of Shares
598,694
Previous 446,573
34.06%
Holding current value
$413,098
Previous $567,000
16.75%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding CYTH
# of Institutions
20Shares Held
2.25MCall Options Held
0Put Options Held
0-
Epiq Capital Group, LLC San Francisco, CA739KShares$510,2030.18% of portfolio
-
Founders Fund V Management, LLC San Francisco, CA481KShares$331,6887.36% of portfolio
-
Geode Capital Management, LLC Boston, MA152KShares$105,1090.0% of portfolio
-
Founders Fund Vi Management, LLC San Francisco, CA110KShares$75,91518.16% of portfolio
-
Black Rock Inc. New York, NY59.5KShares$41,0610.0% of portfolio
About Cyclo Therapeutics, Inc.
- Ticker CYTH
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 8,439,440
- Market Cap $5.82M
- Description
- Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of...